Picture As Pdf Download

Total Page:16

File Type:pdf, Size:1020Kb

Load more

Research A prospective cohort study of trends in self- poisoning, Newcastle, Australia, 1987–2012: plus ça change, plus c’est la même chose Despite ntentional poisoning is a major Abstract massive public health problem and gener- Objective: To examine inhospital mortality and morbidity associated with I ally occurs in the context of delib- self-poisoning with different drug classes over an extended period. increases in erate self-harm and drug misuse. Design, setting and participants: A prospective cohort study over 26 years the number of There are 60 International Statistical (1987–2012) with limited follow-up of patients presenting consecutively to a primary and tertiary referral toxicology centre covering Newcastle, Lake antidepressant Classification of Diseases and Related Health Problems, 10th revision (ICD- Macquarie and Port Stephens, Australia. prescriptions, 10) codes for drug-related deaths. In Main outcome measures: Hospital length of stay, types of drugs ingested, neither rates 2009, these codes together accounted intensive care unit (ICU) admission, requirement for ventilation, inhospital deaths and rates of antidepressant drug use in Australia. of self-harm for 6.4% of male and 5.5% of female total years of potential life lost in Results: Over the study period, there were 17 266 admissions of nor severity of Australia.1 Most deaths are in young patients poisoned by 34 342 substances (16 723 drugs available only on people, and drug-related deaths ac- prescription). The median length of stay was 16 hours, 12.2% of patients antidepressant (2101/17 266) were admitted to an ICU, 7.4% (1281/17 266) were ventilated count for a large proportion of lost poisoning and 78 (0.45%) died in hospital. Patient demographics, social and years of life — causing about 25% of psychiatric factors remained stable over the 26-year period, but case 1 increased completed suicides. The estimated fatality decreased (from 0.77% [15/1955] to 0.17% [7/4060]) as did ICU markedly Australian rate of people hospitalised admissions (19.2% [376/1955] to 6.9% [280/4060]), ventilation (13.7% for self-poisoning of 119 per 100 000 [268/1955] to 4.8% [193/4060]) and LOS. The most frequently ingested population per year2 substantially substances were alcohol, benzodiazepines, paracetamol, antidepressants underestimates total numbers as and antipsychotics. There was a substantial fall in some highly toxic drugs many patients are not admitted or (tricyclic antidepressants, barbiturates, conventional antipsychotics and do not present.3 Most poisonings are theophylline), but increases in less toxic selective serotonin reuptake inhibitors, serotonin–noradrenaline reuptake inhibitors and paracetamol. in young adults and are impulsive A greater than sixfold increase in community antidepressant use was or unplanned. Morbidity and mor- accompanied by only minor changes in overall and antidepressant self- tality from poisoning has proved poisoning rates. surprisingly responsive to targeted Conclusion: Over two decades, there were decreases in poisonings by public health interventions to reduce many highly toxic drugs which were associated with substantial reductions the availability of means to poison in morbidity and inhospital deaths. Despite massive increases in the oneself accidently or deliberately.4,5 number of antidepressant prescriptions, neither rates of self-harm nor the Identification of drugs causing dis- proportion of antidepressant poisonings increased markedly. proportionate numbers of poison- Nicholas A Buckley ings, morbidity or deaths is thus a BMed, FRACP, MD1 key aspect of an effective toxicovigi- and antidepressant self-poisoning, 24 hours/day toxicology treatment Ian M Whyte lance system. and examined changes in prescrib- MB BS(Hons), FRACP, service for a population of about 2,3 FACMT We aimed to examine inhospital mor- ing of and self-poisoning with sev- 500 000. From 1992, ambulances di- eral drugs that have previously been Andrew H Dawson bidity and mortality associated with verted all poisoning presentations 4 MB BS, FRCP, FRACP poisoning in the greater Newcastle identified as having higher relative in the lower Hunter to this service. toxicity in overdose: short-acting bar- Geoffrey K Isbister region over 26 years and to broadly HATS currently has direct clinical 2,3 BSc, FACEM, MD determine what factors have (and biturates, dextropropoxyphene, chlo- responsibility for all poisoned adult ral hydrate, dothiepin, thioridazine, have not) changed over this time, patients in all hospitals in the greater 1 University of Sydney, pheniramine, temazepam, amisul- Sydney, NSW. during which there have been sub- Newcastle region and provides a ter- 2 Calvary Mater Newcastle, pride, alprazolam, venlafaxine and tiary referral service to Maitland and stantial changes in medication use. 10-15 Newcastle, NSW. citalopram. the Hunter Valley. HATS routinely 3 University of Newcastle, In particular, the use of psychotropic Newcastle, NSW. drugs has changed and there have records data on patients who present 4 Royal Prince Alfred Hospital, been large increases in antidepres- to hospital (even if the poisoning is Sydney, NSW. Methods sant prescribing in Australia over uncomplicated).16 Previous studies geoff.isbister@ 6,7 on poisoning in Newcastle17,18 have gmail.com the past three decades. Favourable This is a cohort study of patients pre- and unfavourable effects on popula- senting consecutively after self-poi- shown that no patients were treated tion suicide rates have been postu- soning to the Hunter Area Toxicology exclusively in private hospitals or by doi: 10.5694/mja14.01116 lated for antidepressants.8,9 Thus we Service (HATS) between January their family doctor, indicating that assessed the effect of the increase in 1987 and December 2012. Since 1987, most presentations to medical care Online first 27/04/15 antidepressant prescribing on total HATS has provided a comprehensive facilities are recorded. This cohort 438 MJA 202 (8) · 4 May 2015 Research does not comprehensively cover increased over the first 8 years, but 1 Morbidity and mortality due to self- unintentional childhood (age < 14 since 1995 has been quite stable poisoning, 1987–2012, measured by need years) poisonings. The local human (HATS became well established in for intensive care and ventilation, length research ethics committee has previ- 1994) (Appendix 1). of stay and fatality* ously granted an exemption regard- Of the total admissions, 15 327 (88.8%) Admitted to intensive care unit ing use of the database and patient were attempts at self-harm and the Ventilated information for research. remainder were a mixture of unin- A structured data collection form tentional, iatrogenic and recreational 20% is used by HATS to prospectively self-poisonings. (Data are generally 15% capture information on patient presented for admissions, and may demographics (age, sex, postcode), thus include the same patient with 10% drugs ingested (including doses), different poisonings.) The median co-ingested substances, regular age of admitted patients was 32 5% medications and management and years (range, 14–97 years) and the complications of poisoning.19 At dis- female : male ratio was 1.6 : 1 (10 514 Proportion of admissions 0 charge, further information is col- female, 6711 male and 39 transgender lected (eg, hospital length of stay patient admissions). The median LOS 20 [LOS], psychiatric and substance was 16 hours (interquartile range, misuse diagnoses). Data are rou- 9.3–25.7 hours; total time spent in 15 tinely entered into a fully relational hospital, 15 688 hours). Of the total Microsoft Access database separate admissions, 2101 involved admission 10 (hours) to the hospital’s main medical record of the patient to an intensive care unit Length of stay у 5 system. Data on all patients aged 14 (ICU) (12.2%) and 1281 involved ven- Median length of stay years who presented following self- tilation of the patient (7.4%). There 0 poisoning were analysed. were 78 inpatient deaths (0.45% of admissions). 1.0% Analyses of population-referenced Fatality data (ie, rates) were restricted to We investigated the changes in mor- 0.8% postcodes that predominantly cover bidity and mortality over the study Newcastle, Lake Macquarie and Port period by dividing admissions into 0.6% Stephens. Changes in total self-poi- those in the first 6 years, reported 0.4% soning rates in the four statistical sub- previously,20 and four subsequent divisions in this area were examined 5-year periods (Box 1). Over this died in hospital 0.2% between 1991 and 2011. Changes in period, the rate of admission to ICU 0 rates of self-poisoning using the main dropped from 19.2% (376/1955) to Proportion of patients who antidepressant drug classes (tricy- 6.9% (280/4060) and rate of mechani- clic antidepressants [TCAs], selective cal ventilation from 13.7% (268/1955) 1987–19921993–1997 serotonin reuptake inhibitors [SSRIs], to 4.8% (193/4060). The fatality rate 1998–20022003–20072008–2012 serotonin–noradrenaline reuptake dropped from 0.77% (15/1955) to inhibitors [SNRIs], monoamine oxi- 0.17% (7/4060). The median LOS * Data were divided into five periods with roughly equal patient numbers. dase inhibitors [MAOIs] and other) decreased from 20.5 hours in the were also examined. Data on rates of first 6 years to about 16 hours in all antidepressant drug use in these drug subsequent 5-year periods. 7.7%), d ivorce d (1302, 7.5%), w idowe d classes (standardised by the defined In the 17 266 admissions, a previous (409, 2.4%), in de facto relationships daily dose [DDD]) in Australia history of psychiatric illness (9692, (79, 0.5%), other (13, 0.1%); and data from 1991 to 2011 were taken from 56.1%), previous admission for a psy- were missing for the remainder (467, Australian government publications. chiatric episode (6426, 37.2%), previ- 2.7%). These demographic, social and We have previously shown that these ous suicide attempt (9665, 56.0%) psychiatric factors remained stable, data agreed within two significant and history of alcohol or drug mis- except for a slight rise in the propor- digits with Newcastle-specific data use (8466, 49.0%) were commonly tion of patients reporting previous for a range of medications.11 recorded.
Recommended publications
  • Orphenadrine Hydrochloride 50Mg/5Ml Oral Solution Rare (Affect More Than 1 in 10,000 People) N Forgetting Things More Than Usual

    Orphenadrine Hydrochloride 50Mg/5Ml Oral Solution Rare (Affect More Than 1 in 10,000 People) N Forgetting Things More Than Usual

    Uncommon (affect more than 1 in 1000 people) n Constipation Package Leaflet: Information for the user n Greater sensitivity to things around you or feeling nervous n Feeling light-headed and an unusual feeling of excitement (elation) n Difficulty sleeping or feeling tired. Orphenadrine Hydrochloride 50mg/5ml Oral Solution Rare (affect more than 1 in 10,000 people) n Forgetting things more than usual. Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Reporting of side effects n Keep this leaflet. You may need to read it again. If you get any side effects, talk to your doctor, n If you have any further questions, ask your doctor pharmacist or nurse. This includes any possible side or pharmacist. effects not listed in this leaflet. You can also report n This medicine has been prescribed for you only. side effects directly (see details below). By reporting Do not pass it on to others. It may harm them, even side effects you can help provide more information on if their signs of illness are the same as yours. the safety of this medicine. n If you get any side effects, talk to your doctor or United Kingdom pharmacist. This includes any possible side effects not listed in this Yellow Card Scheme leaflet. See section 4. Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or What is in this leaflet: Apple App Store. 1. What Orphenadrine Hydrochloride Oral Solution is and what is it used for 2.
  • Risk Based Requirements for Medicines Handling

    Risk Based Requirements for Medicines Handling

    Risk based requirements for medicines handling Including requirements for Schedule 4 Restricted medicines Contents 1. Introduction 2 2. Summary of roles and responsibilities 3 3. Schedule 4 Restricted medicines 4 4. Medicines acquisition 4 5. Storage of medicines, including control of access to storage 4 5.1. Staff access to medicines storage areas 5 5.2. Storage of S4R medicines 5 5.3. Storage of S4R medicines for medical emergencies 6 5.4. Access to storage for S4R and S8 medicines 6 5.5. Pharmacy Department access, including after hours 7 5.6. After-hours access to S8 medicines in the Pharmacy Department 7 5.7. Storage of nitrous oxide 8 5.8. Management of patients’ own medicines 8 6. Distribution of medicines 9 6.1. Distribution outside Pharmacy Department operating hours 10 6.2. Distribution of S4R and S8 medicines 10 7. Administration of medicines to patients 11 7.1. Self-administration of scheduled medicines by patients 11 7.2. Administration of S8 medicines 11 8. Supply of medicines to patients 12 8.1. Supply of scheduled medicines to patients by health professionals other than pharmacists 12 9. Record keeping 13 9.1. General record keeping requirements for S4R medicines 13 9.2. Management of the distribution and archiving of S8 registers 14 9.3. Inventories of S4R medicines 14 9.4. Inventories of S8 medicines 15 10. Destruction and discards of S4R and S8 medicines 15 11. Management of oral liquid S4R and S8 medicines 16 12. Cannabis based products 17 13. Management of opioid pharmacotherapy 18 14.
  • Prescription Regulations Summary Chart Who Hold an Approval to Prescribe Methadone from Their

    Prescription Regulations Summary Chart Who Hold an Approval to Prescribe Methadone from Their

    Products included in the Triplicate Prescription Program* This is a reference list provided for convenience. While all generic medication names appear, only sample brand names are provided and it should not be viewed as an all-inclusive listing of all trade names of drugs included in the Triplicate Prescription Program. BUPRENORPHINE METHADONE BuTrans, Suboxone** Metadol, Methadose - May only be prescribed by physicians Prescription regulations summary chart who hold an approval to prescribe methadone from their BUTALBITAL PREPARATIONS provincial regulatory body*** Summary of federal and provincial laws governing prescription drug ordering, Fiorinal, Fiorinal C ¼ & C ½, Pronal, Ratio-Tecnal, records, prescription requirements, and refills Ratio-Tecnal C ¼ & C ½, Trianal, Trianal C ½ METHYLPHENIDATE Biphentin®, Foquest®, and Concerta® brands are excluded Revised 2019 BUTORPHANOL from TPP prescr ip t i o n p a d req u ir e m e n t s (generic versions Butorphanol NS, PMS-Butorphanol, Torbutrol (Vet), of these products require a triplicate presc ription) Torbugesic (Vet) Apo-Methyphenidate, PHL-Methylphenidate, PMS- Prescription regulations DEXTROPROPOXYPHENE Methylphenidate, PMS-Methylphenidate ER, Ratio- None identified Methylphenidate, Ritalin, Ritalin SR, Sandoz- According to the Standards of Practice for Pharmacists and Pharmacy Technicians: Methylphenidate SR, Teva-Methylphenidate ER-C FENTANYL/SUFENTANIL/ALFENTANIL 6.4 Neither a pharmacist nor a pharmacy technician may dispense a drug or blood product under a Alfentanil Injection,
  • Choice of Drugs in the Treatment of Rheumatoid Arthritis

    Choice of Drugs in the Treatment of Rheumatoid Arthritis

    RHEUMATOLOGY IN GENERAL PRACTICE 7 Those with predominant but never exclusive involvement of the terminal finger joint, usually associated with changes in the nail of the same finger; they are serologically negative. There may be a swollen finger with loss of the skin markings-a sort of dactylitis, again serologically negative. (2) Those with a much more severe process which produces loss of movement in the spine and changes in the sacroiliac joints much the same as those in ankylosing spondylitis; unlike ankylosing spondylitis, it produces severe deformity often with ankylosis in peripheral joints. Many of the finger joints become deformed and ankylosed. (3) Those cases indistinguishable from rheumatoid arthritis although the majority are sero-negative. The Stevens Johnson syndrome produces acute effusions, particularly in large joints. It is sometimes associated with the rash of erythema multiforme, always with ulceration in the mouth and genital tract; the mouth ulcers are accompanied by sloughing, unlike those of Beh9et's syndrome which we come to next. BehCet's syndrome, originally described as a combination of orogenital ulceration with relapsing iritis, is now expanded to include skin lesions, other eye lesions, lesions of the central nervous system, thrombophlebitis migrans, and arthropathy (occurring in 64 per cent). The onset is acute, often affecting only a single joint and settling without residual trouble. Choice of drugs in the treatment of rheumatoid arthritis Dr Dudley Hart, M.D., F.R.C.P. (Consultant physician, Westminster Hospital and Medical School) There are many potential drugs for the treatment of rheumatoid disease, but what are we treating in this disorder? Pain in rheumatoid arthritis is but one of the symp- toms.
  • Literature Review of Prescription Analgesics in the Causal Path to Pain

    Literature Review of Prescription Analgesics in the Causal Path to Pain

    Literature Review: Opioids and Death compiled by Bill Stockdale ([email protected]) This review is the result of searches for the terms opioid/opioid-related-disorders and death/ADE done in the PubMed database. This bibliography includes selected articles from the 1,075 found by searching during May, 2008, which represent key findings in the study of opioids. Articles for which there is no abstract are excluded. Also case reports and initial clinical trial reports are excluded. This is a compendium of all articles and do not lead to a specific target. There are three major topics developed in the literature as shown in this table of contents; • Topic One: Opioids in Causal Path to Death (page 1) o Prescription Drug Deaths (page 1) o Illicit Drug Deaths (page 30) o Neonatal Deaths (page 49) • Topic Two: Deaths in Palliative Care and Pain Treatment (page 57) • Topic Three: Pharmacology, Psychology, Origins of Abuse Relating to Death (page 72) • Bibliography (page 77) The three topics are presented below; each is followed in chronological order. Topic One: Opioids in Causal Path to Death Prescription Drug Deaths Karlson et al. describe differences in treatment of acute myocardial infarction, including different opioid use among men and women. The question whether women and men with acute myocardial infarction (AMI) are treated differently is currently debated. In this analysis we compared pharmacological treatments and revascularization procedures during hospitalization and during 1 year of follow-up in 300 women and 621 men who suffered an AMI in 1986 or 1987 at our hospital. During hospitalization, the mean dose of morphine (+/- SD) during the first 3 days was higher in men compared to women (14.5 +/- 15.7 vs.
  • PCF4 Revised Monographs (Since Publication September 2011 to July 2014)

    PCF4 Revised Monographs (Since Publication September 2011 to July 2014)

    www.palliativedrugs.com PCF4 revised monographs (since publication September 2011 to July 2014) Monograph Chapter number Date updated 5HT3 antagonists Chapter 04 Correction Apr-13 5HT3 antagonists Chapter 04 Jun-14 Adjuvant analgesics Chapter 05 Jun-14 Alfentanil Chapter 05 May-14 Amitriptyline Chapter 04 Oct-13 Anaemia Chapter 09 Apr-14 Analgesic drugs and fitness to drive Chapter 19 Jun-14 Anaphylaxis Chapter 27 May-13 Anaphylaxis Chapter 27 Correction Oct-13 Anaphylaxis Chapter 27 Jul-14 Antacids Chapter 01 Sep-12 Antacids Chapter 01 Minor update Jun-14 Antibacterials in palliative care Chapter 06 Sep-12 Antibacterials in palliative care Chapter 06 Minor update Apr-14 Anticoagulants Chapter 02 Minor update Aug-13 Anticoagulants (new) Chapter 02 New May-13 Antidepressants Chapter 04 Oct-13 Anti-emetics Chapter 04 Jun-14 Anti-epileptics pre-synaptic calcium channel blockers Chapter 04 Discontinued May-14 Anti-epileptics sodium channel blockers Chapter 04 Discontinued May-14 Anti-epileptics Chapter 04 Merged monograph May-14 Antifibrinolytics Chapter 02 Aug-13 Antihistaminic antimuscarinic anti-emetics Chapter 04 Jun-14 Antimuscarinics Chapter 01 Correction Apr-13 Antimuscarinics Chapter 01 Apr-14 Antipsychotics Chapter 04 Jun-14 Antitussives Chapter 03 Mar-14 Artificial saliva Chapter 11 Jun-14 Ascorbic acid Chapter 09 Nov-12 Baclofen Chapter 10 Jun-14 Barrier products Chapter 12 Apr-14 Benzodiazepines Chapter 04 Jun-14 Bisphosphonates Chapter 07 Merged monograph Jun-14 Buprenorphine Chapter 05 Jun-13 Buprenorphine Chapter 05 Jun-14
  • Chapter 151 – Antidepressants

    Chapter 151 – Antidepressants

    Crack Cast Show Notes – Skin and Soft Tissue Infections www.canadiem.org Chapter 151 – Antidepressants Key Concepts ❏ Although rarely used for depression, MAOIs are used in the treatment of Parkinson’s disease ❏ Because serious symptoms can occur after a lengthy latent period, patients with reported MAOI overdose should be admitted for 24 hours, regardless of symptoms. Symptoms are characterized by tachycardia, hypertension, and CNS changes, and later cardiovascular collapse. ❏ The primary manifestations of TCA toxicity are seizures, tachycardia, and intraventricular conduction delay. IV sodium bicarbonate should be administered for QRS prolongation. ❏ DO NOT USE PHYSOSTIGMINE IN TCA OVERDOSE ❏ SSRIs are comparatively benign in overdose. ❏ SNRI ingestions can result in seizures, tachycardia, and occasionally intraventricular conduction delay. ❏ The hallmark feature of serotonin syndrome is lower extremity rigidity (spasticity) with spontaneous or inducible clonus, especially at the ankles. ❏ Serotonin syndrome is primarily treated with supportive care, including discontinuation of the offending agent, and benzodiazepines. Sign Post 1) List 7 pharmacodynamic effects of cyclic antidepressants and describe the physiologic result 2) What are the ECG findings associated with TCA toxicity and what are their implications 3) Describe the management of TCA toxicity 4) What are the diagnostic criteria for Serotonin Syndrome? 5) How can you discern between NMS and Serotonin Syndrome? 6) What are the common meds causing Serotonin Syndrome? 7) Describe the management of Serotonin Syndrome 8) What is the primary risk of toxicity in Bupropion? 9) What are the 3 mechanisms by which MAOI toxicity can occur? And what is the clinical syndrome? 10) List 5 foods and 5 classes of meds that can interact to cause MAOI toxicity 11) Describe the management of MAOI toxicity.
  • NORFLEX™ Orphenadrine Citrate 100Mg Tablets

    NORFLEX™ Orphenadrine Citrate 100Mg Tablets

    NORFLEX™ Orphenadrine citrate 100mg tablets Consumer Medicine Information What is in this leaflet Ask your doctor if you have any Before you start to take it questions about why this medicine Tell your doctor or pharmacist if This leaflet answers some common has been prescribed for you. • you have allergies to any other questions about NORFLEX tablets. medicines, foods, preservatives However it does not contain all the or dyes. available information. Your doctor and pharmacist have more Before you take • you have any heart problems. information about this medicine. NORFLEX • you have any liver or kidney If you have any questions about problems. NORFLEX that are not answered When you must not take it Tell your doctor if you are by this leaflet, please ask your Do not take NORFLEX if: pregnant or intend to become doctor or pharmacist. pregnant or you are breast-feeding • you have had an allergic or plan to breast-feed. All medicines have risks and reaction to orphenadrine citrate benefits. Your doctor has weighed or other similar medicines, or Your doctor or pharmacist can the risks of your taking NORFLEX to any of the ingredients listed discuss the risks and benefits against the benefits before at the end of this leaflet. involved. prescribing it for you. • you have any of the following: If you are not sure whether to start If you are worried about taking taking this medicine, talk to your - glaucoma this medicine please talk to your doctor. doctor or pharmacist. (high pressure in the eye); Keep this leaflet with your - intestinal blockage, stomach Taking other medicines medicine as you may want to read ulcer or oesophageal disease; Tell your doctor or pharmacist if it again.
  • Ketamine for Pain Management Memory, and Synapticreceptor Plasticity

    Ketamine for Pain Management Memory, and Synapticreceptor Plasticity

    Ketamine for pain management Rae Frances Bella,*, Eija Anneli Kalsob 05/12/2020 on BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3Fe9CqsdNajmw5ZpjYiu9ivtuEPUMW71Z6zh+GGjvgOe8KmNftAEEuQ== by https://journals.lww.com/painrpts from Downloaded Keywords: Ketamine, Pain management Downloaded from https://journals.lww.com/painrpts Key Points 1. Background 1.1. Basic pharmacology and mechanisms of action 1. There is good evidence that perioperative ketamine of ketamine decreases postoperative pain scores and opioid require- ments, but there is a lack of consensus on dose, for both by Ketamine is commonly used as an analgesic in emergency BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3Fe9CqsdNajmw5ZpjYiu9ivtuEPUMW71Z6zh+GGjvgOe8KmNftAEEuQ== medicine and as an adjuvant drug in the perioperative setting. In bolus and infusion. addition, it is used as a third-line adjuvant drug for opioid-resistant 2. Despite limited evidence, a trial of low-dose intravenous or pain in palliative care and for intractable chronic noncancer pain. subcutaneous ketamine adjuvant to morphine may be More recently, ketamine is increasingly being used to treat major warranted in refractory cancer pain. depression and other mood disorders. 3. There is only very limited evidence for the use of ketamine Ketamine is a phencyclidine derivative that was developed in in chronic noncancer pain and concerns and a lack of the 1960s as an anaesthetic agent. The most important safety data concerning long-term or repeated treatment. pharmacological properties of ketamine are due to it being Importantly, there is no strong evidence to support the a noncompetitive N-methyl-D-aspartate (NMDA) receptor antag- current practice of treating chronic noncancer pain with onist, and its analgesic action at subanaesthetic dose is believed repeated intravenous infusions.
  • Codeine and Its Alternates for Pain and Cough Relief* 2

    Codeine and Its Alternates for Pain and Cough Relief* 2

    Bull. Org. mond. Sante Bull. Wid Hith Org. J 1969, 40. 1-53 Codeine and its Alternates for Pain and Cough Relief* 2. Alternates for Pain Relief NATHAN B. EDDY, M.D.,1 HANS FRIEBEL, Dr med.,2 KLAUS-J)RGEN HAHN, Dr med.3 & HANS HALBACH, Dr med. Dr-Ing. 4 This report-the second of a series on codeine and its alternates for pain and cough relief-contains a detailed evaluation of experimental and clinical data on newer sub- stances having analgesic properties comparable to and in approximately the same range as those ofcodeine. The data are discussed under the headings: analgesic effects in animals; clinical usefulness; side-effects with particular reference to dependence andabuse liability. CONTENTS CARISOPRODOL ............... 1 PRODILIDINE ........... ... .. 42 DEXTROPROPOXYPHENE ........... 6 INDANES .................. 44 DHYDROCODEINE ............... 22 PHTHALIMIDES ............... 44 ETHOHEPTAZINE ............... 24 PYRROLIDINES .......... .... 45 ETYMIDE.. .............. 29 SPECIFIC OPIATE ANTAGONISTS .... 45 FENYRAMIDOL ............... 32 Risum .................... 47 METOFOLINE. .............. 33 REFERENCES ............. ... 48 CARISOPRODOL 5 propanediol carbamate isopropyl carbamate) was evaluated initially for paralysis of the intact animal, After the discovery and development of mepro- depression of spinal reflexes, anticonvulsant effect bamate, further exploitation of the dicarbamate molecule resulted in the preparation of substances 0 which differed widely in their pattern of activity. CH3-CH2-CH2 CH2-O-C-NHCH (CH3)2 One of these, carisoprodol (2-methyl-2-propyl-1,3- \I/ c * This review of the analgesic and antitussive effects of CH3 CH2-0-C-NH2 codeine and its alternates is being published in the Bulletin of the World Health Organization in five instalments. The first, devoted to an assessment of codeine as a pain reliever, was published in Bull.
  • Ensuring Adequate Access for Medical and Scientific Purposes

    Ensuring Adequate Access for Medical and Scientific Purposes

    INTERNATIONAL NARCOTICS CONTROL BOARD Availability of Internationally Controlled Drugs Controlled Internationally of Availability Availability of Internationally Controlled Drugs: Ensuring Adequate Access for Medical and Scientific Purposes Indispensable, adequately available and not unduly restricted UNITED NATIONS Reports published by the International Narcotics Control Board in 2015 TheReport of the International Narcotics Control Board for 2015 (E/INCB/2015/1) is supple- mented by the following reports: Availability of Internationally Controlled Drugs: Ensuring Adequate Access for Medical and Scientific Purposes. Indispensable, adequately available and not unduly restricted (E/INCB/2015/1/Supp.1) Narcotic Drugs: Estimated World Requirements for 2016—Statistics for 2014 (E/INCB/2015/2) Psychotropic Substances: Statistics for 2014—Assessments of Annual Medical and Scientific Requirements for Substances in Schedules II, III and IV of the Convention on Psychotropic Substances of 1971 (E/INCB/2015/3) Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances: Report of the International Narcotics Control Board for 2014 on the Implementation of Article 12 of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 (E/INCB/2015/4) The updated lists of substances under international control, comprising narcotic drugs, psychotropic substances and substances frequently used in the illicit manufacture of narcotic drugs and psychotropic substances, are contained in the latest editions of the annexes to the statistical forms (“Yellow List”, “Green List” and “Red List”), which are also issued by the Board. Contacting the International Narcotics Control Board The secretariat of the Board may be reached at the following address: Vienna International Centre Room E-1339 P.O.
  • NCT02523690 IRB00072940 Evaluating Muscle

    NCT02523690 IRB00072940 Evaluating Muscle

    NCT02523690 IRB00072940 Evaluating Muscle Weakness Improvement With Lorcaserin in ICU (EMILI) Protocol Version: February 10, 2017 (Date in header of protocol, 8/1/2016 was inadvertently not updated) Date: 1 August 2016 Principal Investigator: Dale Needham, MD PhD Application Number: IRB00072940 JHM IRB - eForm A – Protocol Use the section headings to write the JHM IRB eForm A, inserting the appropriate material in each. If a section is not applicable, leave heading in and insert N/A. When submitting JHM IRB eForm A (new or revised), enter the date submitted to the field at the top of JHM IRB eForm A. *************************************************************************************************** 1) Abstract (Provide no more than a one page research abstract briefly stating the problem, the research hypothesis, and the importance of the research.) It was recently discovery that patients recovering from sepsis/critical illness have great difficulty recruiting motor units to generate muscle force. Prior to this discovery, the primary etiology of muscle weakness in these patients was thought to be muscle disease (myopathy) and degeneration of peripheral nerve (neuropathy). However, since motor units are composed of a group of muscle fibers contacted by a single motor neuron arising from the spinal cord, these new findings suggested a problem within the spinal cord as the primary cause of weakness in affected patients. Consistent with these clinical findings in critically ill patients, there is a profound deficit in the excitability of motor neurons in the spinal cord of septic rats. Studies characterizing the impaired excitability in rat motor neurons point to a specific deficit in a slowly inactivating type of sodium current (i.e., the persistent sodium current).